Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
- Conditions
- Bladder Cancer
- Interventions
- Drug: Bacillus Calmette-Guérin (BCG)
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT03504163
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
QI: Patient Satisfaction With Facial Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery
- Conditions
- Skin Cancer
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3000
- Registration Number
- NCT03503240
- Locations
- 🇺🇸
Brigham and Women's Hospital (Data Collection Only), Boston, Massachusetts, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
- Conditions
- Glioma of BrainGlioma of Spinal CordGlioma
- Interventions
- Diagnostic Test: Language paradigms + RS fMRI + one anatomical sequenceBehavioral: Multilingual Aphasia ExaminationDiagnostic Test: Language paradigms + RS fMRI
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03496181
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸City College of New York, New York, New York, United States
🇮🇹IMT School of Advance Studies Lucca, Lucca, Lucca LU, Italy
Short Course Daratumumab in Patients With Multiple Myeloma
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03490344
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
- Conditions
- Thyroid Cancer
- Interventions
- Diagnostic Test: Cerenkov luminescence imaging.
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 102
- Registration Number
- NCT03484884
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
New MRI Biomarkers in Head and Neck Cancers
- Conditions
- Head and Neck CancerThyroid Cancer
- Interventions
- Other: MRI examinations
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03483337
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes
- Conditions
- Non-Communicable Disease
- Interventions
- Behavioral: Questionnaire formsOther: Bio-specimen samples
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10000
- Registration Number
- NCT03473795
- Locations
- 🇳🇬
National Hospital of Abuja (Data collection only), Abuja, Central Business District, Nigeria
🇳🇬Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Improving Planned Surgical Case Duration Accuracy by Leveraging the EHR and Predictive Modeling
- Conditions
- Operative Time
- Interventions
- Other: standard scheduling processOther: assigned a planned case duration value from predictive model
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 683
- Registration Number
- NCT03471377
- Locations
- 🇺🇸
Memoral Sloan Kettering Basking Ridge, New York, New York, United States
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
- Conditions
- Lymphoma
- Interventions
- Radiation: Low- Dose, Local Radiotherapy
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT03465891
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
- Conditions
- Pituitary AdenomaBrain Cancer
- Interventions
- Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET ImagingOther: Blood and Urine samples
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT03465618
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States